Thought Leadership

Latest Report


Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

Despite the initial shock of the COVID-19 pandemic, 2020 was a standout year for biopharma. The top 600 biopharma companies added $487bn in market capitalisation, and smaller biotechs saw a record-breaking $12.8bn raised by IPO and $20bn invested by venture financers. Fortunes in the medical device industry were more divided. Companies developing…

Report library


Evaluate Vantage 2020 Preview

The Evaluate Vantage 2020 Preview predicts a rocky year ahead, with areas of significant growth contrasting with investor uncertainty. The industry closed 2019 with a…


EvaluatePharma Orphan Drug Report 2019

$242bn forecasted orphan drug sales by 2024, one-fifth of the total worldwide pharmaceutical market The EvaluatePharma Orphan Drug Report 2019 arrives at the start of a…